Compare · ALPA vs BSX
ALPA vs BSX
Side-by-side comparison of Alpha Healthcare Acquisition Corp. III (ALPA) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALPA and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $92.25B, about 485.1x ALPA ($190.2M).
- BSX has hit the wire 3 times in the past 4 weeks while ALPA has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 0 for ALPA).
- Company
- Alpha Healthcare Acquisition Corp. III
- Boston Scientific Corporation
- Price
- $9.82-0.41%
- $62.06-5.52%
- Market cap
- $190.2M
- $92.25B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 3
- Recent ratings
- 0
- 25
Alpha Healthcare Acquisition Corp. III
Alpha Healthcare Acquisition Corp. III focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in New York, New York.
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest ALPA
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G filed by Alpha Healthcare Acquisition Corp. III
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G filed by Alpha Healthcare Acquisition Corp. III
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- Alpha Healthcare Acquisition Corp. III filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest BSX
- Data at Heart Rhythm 2026 highlight key Boston Scientific therapies
- Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Boston Scientific announces results for first quarter 2026
- SEC Form EFFECT filed by Boston Scientific Corporation
- SEC Form 424B3 filed by Boston Scientific Corporation
- Boston Scientific downgraded by Raymond James with a new price target
- Boston Scientific announces conference call discussing first quarter 2026 results
- Amendment: SEC Form S-4/A filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints